<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363540">
  <stage>Registered</stage>
  <submitdate>21/01/2013</submitdate>
  <approvaldate>23/01/2013</approvaldate>
  <actrnumber>ACTRN12613000086763</actrnumber>
  <trial_identification>
    <studytitle>Effective dose of remifentanil for control of hemodynamic response to insertion of the Streamlined Liner of the Pharyngeal Airway(SLIPA) </studytitle>
    <scientifictitle>What is effective dose of remifentanil to control hemodynamic response to insertion of the Streamlined Liner of the Pharyngeal Airway(SLIPA) </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hemodynamic response to insertion of the Streamlined Liner of the Pharyngeal Airway(SLIPA)

</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Before insertion of SLIPA, remifentanil (0.5microg/kg, 1.0microg/kg, 1.5microg/kg, 2.0microg/kg ) is injected.
there are 4 different intervention groups who receive their allocated dose once only.
remifentanil is injected intravenously.</interventions>
    <comparator>Before insertion of SLIPA, normal saline is injected </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Systolic Blood Pressure by noninvasive blood pressure cuff</outcome>
      <timepoint>postinsertion 1, 2, 3 min </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Mean Arterial Pressure by noninvasive blood pressure cuff</outcome>
      <timepoint>post insertion 1,2,3 min</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome> Diastolic Blood Pressure by noninvasive blood pressure cuff</outcome>
      <timepoint>Post intubation 1,2,3 min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Heart Rate by electrocardiogram</outcome>
      <timepoint>1, 2, 3 min postinsertion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with healthy and aged 20-65 years old, who were planned general anesthesia.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>cardiovascular or pulmonary disease, reflux esophagitis, obesity (BMI &gt; 30 kg/mÂ²), or were pregnant, or were addicted to opioids, sedatives, or other medications</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The details of the series are kept in a set of sealed envelopes, each bearing only the case number on the outside. After admitting into the operating room and just before the induction of anaesthesia, the numbered envelope was opened and the card inside determined which group the patient would be affiliated to.</concealment>
    <sequence>Randomization into one of the five groups was based on Excel random-number generation </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>True</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>3/01/2011</anticipatedstartdate>
    <actualstartdate>3/01/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state>seoul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Chung-Ang University </primarysponsorname>
    <primarysponsoraddress>Chung-Ang University College of Medicine 224-1 Heukseok-dong, Dongjak-gu Seoul, 156-755, Korea</primarysponsoraddress>
    <primarysponsorcountry>Korea, Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Chung-Ang University </fundingname>
      <fundingaddress>Chung-Ang University College of Medicine 224-1 Heukseok-dong, Dongjak-gu Seoul, 156-755, Korea</fundingaddress>
      <fundingcountry>Korea, Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A single administration of remifentanil can effectively suppress hemodynamic changes due to the insertion of Streamlined Liner of the Pharyngeal Airway. What  is the Effective dose of remifentanil needed to suppress hemodynamic response from Streamlined Liner of the Pharyngeal Airway insertion?</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional Board of Chung-Ang University School of Medicine</ethicname>
      <ethicaddress>Chung-Ang University College of Medicine 224-1 Heukseok-dong, Dongjak-gu Seoul, 156-755, Korea </ethicaddress>
      <ethicapprovaldate>27/12/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Korea, Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Hyun Kang </name>
      <address>Department of Anaesthesiology and Pain Medicine Chung-Ang University College of Medicine 224-1 Heukseok-dong, Dongjak-gu Seoul, 156-755, Korea </address>
      <phone>+82-2-6299-2571, 2579, 2586 </phone>
      <fax />
      <email>roman00@naver.com </email>
      <country>Korea, Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Hyun Kang </name>
      <address>Department of Anaesthesiology and Pain Medicine Chung-Ang University College of Medicine 224-1 Heukseok-dong, Dongjak-gu Seoul, 156-755, Korea </address>
      <phone>+82-2-6299-2571, 2579, 2586 </phone>
      <fax>+82-2-6299-2585 </fax>
      <email>roman00@naver.com </email>
      <country>Korea, Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Hyun Kang </name>
      <address>Department of Anaesthesiology and Pain Medicine Chung-Ang University College of Medicine 224-1 Heukseok-dong, Dongjak-gu Seoul, 156-755, Korea </address>
      <phone>+82-2-6299-2571, 2579, 2586 </phone>
      <fax />
      <email>roman00@naver.com </email>
      <country>Korea, Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>